Discussion about this post

User's avatar
Zishi Wu's avatar

Thanks for the followup coverage on Stride. I agree it's no longer a no-brainer price like it was in the $60s, but not bad risk-reward assuming execution and regulatory risks are managed. What do you think about companies adjacent to Stride like Adtalem (ATGE)? They train about 10% of new nurses. Recently their NCLEX exam pass rate dipped below required 80% so market sold them off due to fears but management said they are working to fix that. It's an execution risk, but I think the moat of training nurses might be stronger than K-12 learning and career services offered by Stride, given a projected nursing shortage in America.

No posts

Ready for more?